Palvella Therapeutics’ (PVLA) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research note published on Tuesday,Benzinga reports. They currently have a $38.00 price target on the stock.

Several other equities research analysts have also recently issued reports on PVLA. TD Cowen initiated coverage on shares of Palvella Therapeutics in a research report on Wednesday, February 5th. They issued a “buy” rating and a $44.00 price objective for the company. Cantor Fitzgerald initiated coverage on shares of Palvella Therapeutics in a research report on Wednesday, December 18th. They issued an “overweight” rating for the company.

Palvella Therapeutics Stock Performance

Palvella Therapeutics stock opened at $20.00 on Tuesday. The stock has a market cap of $224.40 million, a PE ratio of -1.65 and a beta of 0.68. Palvella Therapeutics has a 1 year low of $6.20 and a 1 year high of $22.32. The firm has a 50-day moving average of $13.30.

Insider Activity

In other Palvella Therapeutics news, Director George M. Jenkins purchased 4,000 shares of Palvella Therapeutics stock in a transaction dated Wednesday, December 18th. The stock was acquired at an average price of $12.93 per share, for a total transaction of $51,720.00. Following the acquisition, the director now owns 180,671 shares in the company, valued at $2,336,076.03. This trade represents a 2.26 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 6.39% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

Several large investors have recently modified their holdings of the business. Renaissance Technologies LLC bought a new position in shares of Palvella Therapeutics during the 4th quarter worth approximately $256,000. ADAR1 Capital Management LLC bought a new position in shares of Palvella Therapeutics during the 4th quarter worth approximately $1,736,000. Geode Capital Management LLC bought a new position in shares of Palvella Therapeutics during the 4th quarter worth approximately $171,000. Finally, BML Capital Management LLC bought a new position in shares of Palvella Therapeutics during the 4th quarter worth approximately $506,000. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.